BRAF V600E potentially determines "Oncological Resectability" for "Technically Resectable" colorectal liver metastases.
BRAF V600E potentially determines "Oncological Resectability" for "Technically Resectable" colorectal liver metastases.
复制标题
DOI：
10.1002/cam4.4227
复制
发表时间：
2021-10
期刊：
影响因子：
4
通讯作者：
Yoshino T
中科院分区：
文献类型：
--
作者：
Kobayashi S;Takahashi S;Nomura S;Kojima M;Kudo M;Sugimoto M;Konishi M;Gotohda N;Taniguchi H;Yoshino T
尽管存在关于BRAF V600 E突变（mBRAF）的结直肠肝转移（CRLM）肝切除术后生存结局较差的报告，但mBRAF检测在技术上可切除病例中的作用仍不清楚。进行了一项单中心回顾性研究，以调查2005年1月至2017年12月期间接受前期肝切除术治疗单独可切除CRLM伴mBRAF患者的生存结局，并将其与不可切除的mBRAF病例进行比较。在172例因单独可切除CRLM而接受初始肝切除术的患者中，分别在5例（2.9%）、73例（42.4%）和93例（54.7%）患者中观察到mBRAF、RAS突变（mRAS）和野生型RAS/BRAF（wtRAS/BRAF）。中位随访期为72.8个月，mBRAF与OS显著缩短相关（中位数，14.4个月）比wtRAS/BRAF（中位数，未达到[NR]）（风险比[HR]，27.6; p < 0.001）和mRAS（中位数，NR）（HR，9.9; p < 0.001），mBRAF在多变量分析中的所有指标中具有最高HR（HR，17.0; p < 0.001）。CRLM伴mBRAF患者的前期肝切除术后的中位OS与28例接受全身化疗治疗的不可切除CRLM伴mBRAF患者的中位OS相同（中位数，17.2个月）（HR，0.78; p = 0.65）。当技术上可切除的CRLM合并mBRAF时，其生存结局与不可切除的病例一样差;因此，应将mBRAF患者视为肿瘤学不可切除。CRLM患者应接受治疗前mBRAF检测，无论技术可切除性如何。 临床试验注册号：UMIN 000034557。进行了一项单中心回顾性研究，以调查2005年1月至2017年12月期间接受前期肝切除术治疗BRAF V600 E突变的孤立可切除CRLM患者的生存结局，并将其与突变的不可切除病例进行比较。当技术上可切除的CRLM合并BRAF V600 E时，其生存结局与不可切除的病例一样差;因此，应将携带突变的患者视为肿瘤学不可切除。
Despite reports on poor survival outcomes after hepatectomy for colorectal liver metastases (CRLM) with BRAF V600E mutation (mBRAF) exist, the role of mBRAF testing for technically resectable cases remains unclear. A single‐center retrospective study was performed to investigate the survival outcomes of patients who underwent upfront hepatectomy for solitary resectable CRLM with mBRAF between January 2005 and December 2017 and to compare them with those of unresectable cases with mBRAF. Of 172 patients who underwent initial hepatectomy for solitary resectable CRLM, mBRAF, RAS mutations (mRAS), and wild‐type RAS/BRAF (wtRAS/BRAF) were observed in 5 (2.9%), 73 (42.4%), and 93 (54.7%) patients, respectively. With a median follow‐up period of 72.8 months, mBRAF was associated with a significantly shorter OS (median, 14.4 months) than wtRAS/BRAF (median, not reached [NR]) (hazard ratio [HR], 27.6; p < 0.001) and mRAS (median, NR) (HR, 9.9; p < 0.001), and mBRAF had the highest HR among all the indicators in the multivariable analysis (HR, 17.0; p < 0.001). The median OS after upfront hepatectomy for CRLM with mBRAF was identical to that of 28 unresectable CRLM with mBRAF that were treated with systemic chemotherapy (median, 17.2 months) (HR, 0.78; p = 0.65). When technically resectable CRLM are complicated with mBRAF, its survival outcome becomes as poor as unresectable cases; therefore, those with mBRAF should be considered as oncologically unresectable. Patients with CRLM should undergo pre‐treatment mBRAF testing regardless of technical resectability. Clinical trial registration number: UMIN000034557. A single‐center retrospective study was performed to investigate the survival outcomes of patients who underwent upfront hepatectomy for solitary resectable CRLM with BRAF V600E mutation between January 2005 and December 2017 and to compare them with those of unresectable cases with the mutation. When technically resectable CRLM are complicated with BRAF V600E, its survival outcome becomes as poor as unresectable cases; therefore, those with the mutation should be considered as oncologically unresectable.
登录
查看更多内容
BRAF突变是晚期和复发性结直肠癌的强大预后因素。
影响因子：
8.8
作者：
Yokota, T.;Ura, T.;Shibata, N.;Takahari, D.;Shitara, K.;Nomura, M.;Kondo, C.;Mizota, A.;Utsunomiya, S.;Muro, K.;Yatabe, Y.
通讯作者：
Yatabe, Y.
对医疗统计信息的自由使用的易于使用的软件“ EZR”的调查。
影响因子：
4.8
作者：
Kanda Y
通讯作者：
Kanda Y
影响因子：
9
作者：
Gagniere, Johan;Dupre, Aurelien;D'Angelica, Michael, I
通讯作者：
D'Angelica, Michael, I
DOI：
10.1097/pas.0b013e31824430d7
发表时间：
2012-05
期刊：
The American journal of surgical pathology
影响因子：
--
作者：
Pai RK;Jayachandran P;Koong AC;Chang DT;Kwok S;Ma L;Arber DA;Balise RR;Tubbs RR;Shadrach B;Pai RK
通讯作者：
Pai RK
影响因子：
82.9
作者：
Nakamura, Yoshiaki;Taniguchi, Hiroya;Yoshino, Takayuki
通讯作者：
Yoshino, Takayuki